(Q40320232)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Ibrahim Yakoub-Agha

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

A Boumendil

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

H Finel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

S Choquet

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

G de Rosa

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

F Falzetti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

R Scime

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

G Kobbe

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

F Ferrara

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Delmer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

H Sayer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

S Amorim

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

R Bouabdallah

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

J Finke

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

G Salles

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

E Faber

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

E Nicolas-Virelizier

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

L Facchini

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

D Vallisa

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

E Zuffa

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Sureda

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

P Dreger

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

EBMT Lymphoma Working Party

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

16 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

212-218

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/bmt.2015.273

29 February 2020

exact match

0 references

cites work

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

A Phase 1-11 Study of High-Dose Thiotepa, Busulfan and Cyclophosphamide as a Preparative Regimen for Autologous Transplantation for Malignant Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.273

Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa.

21 January 2018

1 reference

12 December 2020

Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma

1 reference

12 December 2020

High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease

1 reference

12 December 2020

BU, melphalan and thiotepa as a preparative regimen for auto-transplantation in Hodgkin's disease

1 reference

12 December 2020

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

1 reference

12 December 2020

High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin’s lymphoma

1 reference

12 December 2020

High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation

1 reference

12 December 2020

Identifiers

DOI

10.1038/BMT.2015.273

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26569093%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

29 February 2020

0 references

1 reference